- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01169935
Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)
February 4, 2013 updated by: University of Edinburgh
In Vivo Tracking of Magnetically-labelled Human Mononuclear Cells Using MRI Scanning
Treatment of a wide range of diseases using stem cells and other types of cell appears promising.
Following administration of cells it is often not clear where exactly the cells have gone and how many of them have reached the target site.
This has been one of the challenges of developing these treatment options further.
We have developed a method of labelling human cells with a magnetic resonance imaging (MRI) "contrast agent" which contains tiny iron filings.
Following intravenous administration it is possible to see where the iron-labelled cells have gone using MRI scanning.
We would like to do is to demonstrate that these cells behave normally and migrate to a site of inflammation.
We plan to induce an area of inflammation in the forearm of healthy volunteers using the Mantoux test (a test of immunity against tuberculosis) before giving the labelled cells intravenously.
After the Mantoux test we will give these volunteers iron-labelled cells and do MRI scans of their forearm to determine whether these cells can be seen accumulating in the target site.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Scotland
-
Edinburgh, Scotland, United Kingdom, EH16SU4
- University of Edinburgh / Royal Infirmary of Edinburgh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female volunteers age 18 to 65 years
- Previous vaccine for tuberculosis more than 5 years ago
Exclusion Criteria:
- pregnancy / breast feeding
- Contra-indication to MRI scanning
- Inability or refusal to give informed consent
- Renal failure (eGFR <25mL/min) or hepatic dysfunction (Child's B or C)
- HIV/hepatitis B/hepatitis C/HTLV/syphilis
- Active malignant disease
- Anaemia
- Blood dyscrasia
- High risk of allergy to protamine sulphate (fish allergy, infertile men, vasectomy)
- Known history of tuberculosis infection.
- History of prolonged residence (> 6 months) in a region or country with a high prevalence of tuberculosis.
- Previous Mantoux reaction of 15mm of greater.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of Intra-dermal SPIO
MRI scanning before and after intra-dermal injection of SPIO.
|
single dose, intradermal
|
Experimental: Mantoux, Venesection, Labelled cells
Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
|
single dose, intradermal
single dose, intravenous
|
Experimental: Mantoux, Apheresis, Labelled cells
Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
|
single dose, intradermal
single dose, intravenous
|
Experimental: Mantoux, Administration of Endorem
Mantoux test then MRI scanning before and after administration of Endorem.
|
single dose, intradermal
single dose, intravenous
|
Experimental: Mantoux only
Mantoux test then serial MRI scanning.
|
single dose, intradermal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in signal intensity in the region of interest on MRI scanning
Time Frame: 0 hours, 24 hours, 48 hours, 3 - 5 days
|
0 hours, 24 hours, 48 hours, 3 - 5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jenny M Richards, MBChB MRCS, University of Edinburgh
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2010
Primary Completion (Actual)
April 1, 2011
Study Registration Dates
First Submitted
July 23, 2010
First Submitted That Met QC Criteria
July 23, 2010
First Posted (Estimate)
July 26, 2010
Study Record Updates
Last Update Posted (Estimate)
February 5, 2013
Last Update Submitted That Met QC Criteria
February 4, 2013
Last Verified
February 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10/S1102/31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Administration of intra-dermal Endorem
-
Ministry of Science and Technology, IndiaCompleted
-
University of EdinburghRoyal College of Surgeons of Edinburgh; Translational Medicine Research CollaborationCompletedHealthy VolunteerUnited Kingdom
-
AnergisTerminatedAllergy | Allergic RhinitisSwitzerland
-
University of EdinburghBritish Heart FoundationSuspendedMyocardial Infarction | InflammationUnited Kingdom
-
Rennes University HospitalTerminatedHepatocellular CarcinomaFrance
-
University of UtahCompletedBreast Cancer | Reconstructive SurgeryUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingPostoperative Complications | Peritoneal Neoplasms | Fluid Therapy | Hyperthermic Intraperitoneal Chemotherapy | Intraoperative Care | Cytoreduction Surgical Procedures | Albumin Administration
-
Groupe Hospitalier Paris Saint JosephRecruiting
-
Aldeyra Therapeutics, Inc.CompletedSjogren-Larsson SyndromeUnited States
-
General Hospital of Shenyang Military RegionCompleted